Eikon pulls in $351M as lead drug begins Phase III journey

Eikon Therapeutics Secures $351M Funding for Cancer Drug Development

Eikon Therapeutics raised $351 million in a Series D funding round1 2 4
Total funding raised since 2019 launch now exceeds $1.1 billion1
Lead drug EIK1001 has entered Phase III trials for advanced melanoma1 4
Clinical studies ongoing in 28 countries across 5 continents1 4

## Pipeline Highlights:

EIK1001:
TLR7/8 agonist in Phase III for melanoma, Phase II for lung cancer1 2 4

EIK1003:
Selective PARP1 inhibitor in Phase I for breast, ovarian, prostate, pancreatic cancers2 4

EIK1004:
CNS-penetrant PARP1 inhibitor entering Phase I for brain cancers2 4
Early-stage pipeline includes androgen receptor antagonists and WRN inhibitor4

## Company Background:

Eikon Therapeutics, founded in 2019, is led by former Merck executive Roger Perlmutter1 2. The company utilizes proprietary single molecule tracking technology to uncover biological processes in living cells with high precision4. This approach integrates automation, high-performance computing, and advanced data science to accelerate drug discovery4.

## Funding Details:

The $351 million Series D round was supported by existing investors and new participants, including mutual funds, wealth funds, and technology-focused venture firms like Lux Capital and Alexandria Venture Investments1 4. This latest funding will support ongoing clinical studies and further pipeline development1 4.

## Market Context:

Eikon's substantial funding round stands out in the current biotech financing landscape, where early-stage funding has declined significantly since 20213. The company's progress to Phase III trials and diverse pipeline make it an attractive investment in a challenging market for biotech IPOs and venture capital3.